How Long Should You Stop Semaglutide Before Surgery to Avoid Stomach Content Risks?
Semaglutide users had six times higher rates of residual stomach content before procedures, but stopping the drug 14-21 days beforehand normalized the risk.
Quick Facts
What This Study Found
Semaglutide users had significantly higher rates of increased residual gastric content (20.3% vs 3.2%, p<0.001). Discontinuation >21 days in patients with digestive symptoms and >14 days in those without symptoms resulted in RGC comparable to non-users (OR 0.77, 95% CI 0.22-2.01).
Key Numbers
Various perioperative semaglutide interruption intervals compared. Residual gastric content assessed by esophagogastroduodenoscopy.
How They Did This
Single-center retrospective chart review at a tertiary hospital. 1,094 patients undergoing esophagogastroduodenoscopy under deep sedation or general anesthesia (July 2021-July 2023) were divided into semaglutide (n=123) and non-semaglutide (n=971) groups. Increased RGC defined as any solid content or >0.8 mL/kg fluid. Univariate and multivariate logistic regression analyzed factors associated with increased RGC.
Why This Research Matters
Semaglutide and other GLP-1 receptor agonist peptides slow gastric emptying, which can leave food in the stomach during procedures requiring sedation — raising the risk of aspiration into the lungs. This study provides concrete timelines for when to stop the drug before surgery.
The Bigger Picture
As GLP-1 peptide drugs like semaglutide become widely prescribed for obesity and diabetes, perioperative safety becomes a population-level concern. This study helps anesthesiologists and surgeons develop evidence-based preoperative protocols for the millions of patients now taking these medications.
What This Study Doesn't Tell Us
Retrospective single-center design limits generalizability. RGC measurement from suction canisters is imprecise compared to gastric ultrasound. Semaglutide group was relatively small (n=123). Different semaglutide doses and formulations were not separately analyzed. Results may not apply to other GLP-1 agonists with different half-lives.
Questions This Raises
- ?Do other GLP-1 receptor agonist peptides like tirzepatide require similar or different discontinuation intervals?
- ?Could point-of-care gastric ultrasound replace fixed discontinuation timelines for personalized risk assessment?
- ?Are the aspiration risks different for oral vs injectable semaglutide formulations?
Trust & Context
- Key Stat:
- 20.3% vs 3.2% Semaglutide users were over six times more likely to have increased residual gastric content compared to non-users undergoing endoscopy
- Evidence Grade:
- Rated moderate: large sample (1,094 patients), clear statistical significance, and clinically actionable findings, but limited by retrospective single-center design and imprecise RGC measurement methods.
- Study Age:
- Published in 2024. Highly timely given the rapid increase in GLP-1 peptide prescriptions worldwide.
- Original Title:
- Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study.
- Published In:
- Journal of clinical anesthesia, 99, 111668 (2024)
- Authors:
- Santos, Leonardo Barbosa, Mizubuti, Glenio B(2), da Silva, Leopoldo Muniz, Silveira, Saullo Queiroz, Nersessian, Rafael Souza Fava, Abib, Arthur de Campos Vieira, Bellicieri, Fernando Nardy, Lima, Helidea de Oliveira, Ho, Anthony M-H, Dos Anjos, Gabriel Silva, de Moura, Diogo Turiani Hourneaux, de Moura, Eduardo Guimarães Hourneuax, Vieira, Joaquim Edson
- Database ID:
- RPEP-09203
Evidence Hierarchy
Frequently Asked Questions
How long should you stop semaglutide before surgery?
This study found that stopping semaglutide more than 21 days before a procedure (or more than 14 days if you have no digestive symptoms) brings stomach content levels back to normal, reducing aspiration risk under anesthesia.
Does semaglutide increase surgery risks?
Yes — semaglutide users had over six times the rate of residual stomach content (20.3% vs 3.2%) before procedures under sedation, which increases the risk of food or fluid entering the lungs during anesthesia.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09203APA
Santos, Leonardo Barbosa; Mizubuti, Glenio B; da Silva, Leopoldo Muniz; Silveira, Saullo Queiroz; Nersessian, Rafael Souza Fava; Abib, Arthur de Campos Vieira; Bellicieri, Fernando Nardy; Lima, Helidea de Oliveira; Ho, Anthony M-H; Dos Anjos, Gabriel Silva; de Moura, Diogo Turiani Hourneaux; de Moura, Eduardo Guimarães Hourneuax; Vieira, Joaquim Edson. (2024). Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study.. Journal of clinical anesthesia, 99, 111668. https://doi.org/10.1016/j.jclinane.2024.111668
MLA
Santos, Leonardo Barbosa, et al. "Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study.." Journal of clinical anesthesia, 2024. https://doi.org/10.1016/j.jclinane.2024.111668
RethinkPeptides
RethinkPeptides Research Database. "Effect of various perioperative semaglutide interruption int..." RPEP-09203. Retrieved from https://rethinkpeptides.com/research/santos-2024-effect-of-various-perioperative
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.